Preliminary evaluation of a new psychotropic drug, lenperone, in the treatment of acute schizophrenia.
An open trial of a new psychotropic drug, lenperone, was carried out in 10 patients with acute schizophrenia. The duration of treatment was 28 days and the maximum dose administered was 60 mg per day. A pronounced antipsychotic effect was seen in half of the patients, although all 10 patients showed a pharmacological response to the drug. The incidence of side-effects was low. Haematological, biochemical and electrocardiographic tests failed to demonstrate any abnormality due to treatment.